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The Development of Heart Failure
in Patients With Diabetes Mellitus
and Pre-Clinical Diastolic Dysfunction
A Population-Based Study
Aaron M. From, MD,* Christopher G. Scott, MS,† Horng H. Chen, MBBCH*
Rochester, Minnesota
Objectives The purpose of this study was to evaluate the outcomes of pre-clinical diastolic dysfunction in diabetic patients.
Background Studies have reported a high prevalence of pre-clinical diastolic dysfunction among patients with diabetes mellitus.
Methods We identified all diabetic patients with a tissue Doppler imaging assessment of diastolic function in Olmsted
County, Minnesota, from 2001 to 2007. Diastolic dysfunction was defined as a passive transmitral left ven-
tricular (LV) inflow velocity to tissue Doppler imaging velocity of the medial mitral annulus during passive filling
(E/e=) ratio 15. The main outcome was the development of heart failure (HF). Secondary outcomes were the
development of atrial fibrillation and death.
Results Overall, 1,760 diabetic patients with a tissue Doppler echocardiographic assessment of diastolic function were identi-
fied; 411 (23%) patients had diastolic dysfunction. Using multivariable Cox’s proportional hazard modeling, we deter-
mined that for every 1-U increase in the passive transmitral LV inflow velocity to tissue Doppler imaging velocity of the
medial mitral annulus during passive filling (E/e=) ratio, the hazard ratio (HR) of HF increased by 3% (HR: 1.03; 95%
confidence interval [CI]: 1.01 to 1.06; p  0.006) and that diastolic dysfunction was associated with the subsequent
development of HF after adjustment for age, sex, body mass index, hypertension, coronary disease, and echocardio-
graphic parameters (HR: 1.61; 95% CI: 1.17 to 2.20; p  0.003). The cumulative probability of the development of
HF at 5 years for diabetic patients with diastolic dysfunction was 36.9% compared with 16.8% for patients without
diastolic dysfunction (p  0.001). Furthermore, diabetic patients with diastolic dysfunction had a significantly higher
mortality rate compared with those without diastolic dysfunction.
Conclusions We demonstrated that an increase in the passive transmitral LV inflow velocity to tissue Doppler imaging velocity of
the medial mitral annulus during passive filling (E/e=) ratio in diabetic patients is associated with the subsequent de-
velopment of HF and increased mortality independent of hypertension, coronary disease, or other echocardiographic
parameters. (J Am Coll Cardiol 2010;55:300–5) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.003p
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oiabetes mellitus (DM) is often complicated by concomitant
ypertension and associated with increased cardiovascular
omplications, the most common of which are coronary artery
iseases and the subsequent development of heart failure (HF).
owever, the existence of a primary myocardial disease in
iabetic patients, diabetic cardiomyopathy, has been proposed
1–11). The existence of diabetic cardiomyopathy was first
roposed by Rubler et al. (10) in 1972 on the basis of
rom the *Department of Medicine, Division of Cardiovascular Diseases and the
Division of Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota. This
tudy was funded by the National Institutes of Health (HL 76611-04-P4) and made
ossible by the Rochester Epidemiology Project (grant R01-AR30582 from the
ational Institute of Arthritis, Musculoskeletal and Skin Diseases).p
Manuscript received July 24, 2009; revised manuscript received December 2, 2009,
ccepted December 7, 2009.ostmortem findings. Subsequently, abnormalities in both
ystolic and diastolic performance in diabetic subjects have
een demonstrated in animal and human studies. The patho-
enesis of this left ventricular (LV) dysfunction in diabetic
atients is not clearly understood. Microangiopathy, increased
xtracellular collagen deposition, and abnormalities in calcium
See page 306
ransport alone or in combination are considered to be associ-
ted with this dysfunction (12–14). Furthermore, the evidence
ndicates that myocardial damage in diabetic patients affects
iastolic function before systolic function (15). Unfortunately,
here have been few population-based studies to evaluate the
utcomes of pre-clinical diastolic dysfunction in diabetic
atients (16).
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January 26, 2010:300–5 HF in Diabetic Diastolic DysfunctionThe combination of pulsed tissue Doppler imaging velocity
f the medial mitral annulus during passive filling (e=) with the
arly passive transmitral inflow velocity (E) has been validated
s a reliable index of LV filling pressure (17). Studies have
emonstrated a reduction of annular e= in type 2 diabetes
ellitus (DM) and that an increased E/e= ratio was associated
ith left atrial enlargement and correlated independently with
lycosylated hemoglobin (11). Thus, the E/e= ratio may be used
o detect and follow the progression of diastolic dysfunction in
iabetic patients (18).
The objective of our study was to determine whether
here is an association between pre-clinical diastolic dys-
unction in DM patients and the subsequent development
f HF. We used tissue Doppler imaging indices of diastolic
ysfunction as the measure of cardiac dysfunction because
issue Doppler imaging indices correlate well with intracar-
iac pressure tracings of ventricular filling in patients with
nd without DM. We hypothesized that diastolic dysfunc-
ion in DM will be associated with the increased risk of the
evelopment of subsequent HF.
ethods
tudy setting. This study was conducted in the Olmsted
ounty, Minnesota, population. Health care providers in
lmsted County include the Mayo Clinic, Olmsted Med-
cal Center, and a handful of private practitioners. Medical
ecords for all providers are available for review by using the
omprehensive record-linkage system provided by the
ochester Epidemiology Project. The Rochester Epidemi-
logy Project allows the indexing of all medical records of
lmsted County residents according to clinical and patho-
ogical diagnoses, surgical procedures, and billing informa-
ion. Death certificates are also indexed according to cause
f death. Records are quite complete because 90% of the
opulation receives care at Mayo Clinic or Olmsted Medical
enter, and residents are seen on average every 3 years at the
ayo Clinic (19). The potential of the data source was
escribed elsewhere (19).
M and echocardiography correlation cohort. After ap-
roval by the Mayo Clinic and the Olmsted County
edical Center Institutional Review Boards, we retrospec-
ively identified all diabetic patients with a tissue Doppler
maging assessment of diastolic function in the Olmsted
ounty, Minnesota, population. To avoid inclusion of
atients in whom the diagnosis of HF was triggered by the
esults of echocardiography, we excluded patients who were
iagnosed within 30 days after the echocardiogram. Fur-
hermore, patients were excluded if the diagnosis of HF was
ade before the echocardiogram or if severe mitral or aortic
alve regurgitation or stenosis was present. The main
utcome was the development of HF.
We identified patients with a new diagnosis of DM in
lmsted County from 1996 through 2006 using the Inter-
ational Classification of Disease-9th Revision code 250.
his code has been validated in Olmsted County previously dith an accuracy of 98% (20).
mong these patients, we iden-
ified those who subsequently de-
eloped HF by using Interna-
ional Classification of Disease-
th Revision code 428. This code
as also been validated in Olm-
ted County: 90% of patients
ith this code have a physician
iagnosis of HF and 82% of pa-
ients with this code meet Fra-
ingham Criteria for HF (21).
ll echocardiograms were per-
ormed from September 2001
hrough June 2007. Ejection
raction was evaluated by a modification of the method of
uinones et al. (22). Doppler echocardiography was per-
ormed to determine the early mitral inflow velocity (E) and
issue Doppler imaging evaluation was performed of the
edial mitral annulus velocity during passive filling (e=) as
reviously described (17). Diastolic dysfunction was defined
s an E/e= ratio 15, as previously described (17). Left
entricular size and wall thickness were measured using the
-dimensional image if available. Otherwise, the M-mode
easurement was used.
tatistical analysis. Categorical variables were summarized
s percentages and continuous variables as mean  SD.
omparison between groups was based on 2-sample t tests
or continuous variables and Pearson’s chi-square test for
ategorical variables. The major end point was the develop-
ent of HF. Other end points analyzed included death and
trial fibrillation. Kaplan-Meier analysis was performed to
stimate probabilities of events and the probabilities were
ompared among groups using the log-rank test statistic.
nivariable and multivariable associations of clinical and
chocardiographic variables with each end point were as-
essed with Cox’s proportional hazard modeling using the
vent of interest and time from 30 days after the echocar-
iogram to the date of the event or last follow-up as the
utcome. In patients without an event, the date of the latest
ollow-up was the time of the data collection (June 2007) or
ate of death. Patients with missing data were excluded
rom the multivariable analysis. However, fitting the model
ith missing indicators revealed similar results. Analyses
ere performed using JMP version 6.0.0 (SAS Institute
nc., Cary, North Carolina).
esults
f the 12,014 Olmsted County residents with DM, 4,571
ad echocardiographic data. From this group, we identified
,770 diabetic patients with a tissue Doppler echocardio-
raphic assessment of diastolic dysfunction. We excluded
45 patients with a diagnosis of HF before the echocardio-
ram, 130 patients with a diagnosis of HF made within 30
Abbreviations
and Acronyms
CI  confidence interval
DM  diabetes mellitus
E  passive transmitral left
ventricular inflow velocity
e=  tissue Doppler
imaging velocity of the
medial mitral annulus
during passive filling
HF  heart failure
HR  hazard ratio
LV  left ventricularays after the echocardiogram, 1 patient with severe mitral
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HF in Diabetic Diastolic Dysfunction January 26, 2010:300–5r aortic valve regurgitation, and 34 patients with severe
ortic or mitral stenosis. Overall, 1,760 diabetic patients
ere included in this study and 411 (23%) patients had
re-clinical diastolic dysfunction defined as an E/e= 15
ithout a diagnosis of HF. Average time from echocardio-
ram to death or latest follow-up was 2.9  1.8 years.
aseline characteristics are shown in Table 1. The DM
atients with diastolic dysfunction were older, were more
ften female, and had a higher prevalence of hypertension
nd coronary artery diseases compared with the DM pa-
ients without diastolic dysfunction. Echocardiographic
ndings of DM patients with diastolic dysfunction include
reater left atrial volume and LV mass index.
Using Cox’s proportional hazard modeling, we deter-
ined that the E/e= ratio was independently associated with
he subsequent development of HF after adjustment for age,
ex, body mass index, hypertension, coronary disease, ejec-
ion fraction, left atrial volume, deceleration time, and LV
ass index. This analysis suggests that for every 1-unit
ncrease in the mitral E/e= ratio, the risk of HF increases by
% (hazard ratio [HR]: 1.03, 95% confidence interval [CI]:
.01 to 1.06; p  0.006).
Diastolic dysfunction defined as an E/e= 15 was pre-
ictive of HF in Kaplan-Meier analysis (Fig. 1). The
umulative probability of the development of HF for DM
atients with diastolic dysfunction was 13.1% at 1 year and
6.9% at 5 years compared with 5.2% at 1 year and 16.8%
t 5 years for DM patients without diastolic dysfunction
p  0.001). In multivariable Cox’s proportional hazard
egression analysis, we determined that diastolic dysfunction
as associated with the subsequent development of HF
fter adjustment for age, sex, body mass index, hyperten-
Baseline CharacteristicsTable 1 Baseline Characteristics
Characteristic
Overall
(n  1,760)
Age, yrs 60 14
Male sex 863 (49)
Body mass index, kg/m2* 33 14
Hypertension 1,507 (86)
Coronary disease 632 (36)
Ejection fraction, %† 62 9
E/e= ratio 13 6
Left atrial volume‡ 63 24
Deceleration time§ 217 50
LV mass index, g/m2 97 25
Septal thickness, mm¶ 10.9 1.9
Posterior wall thickness, mm# 10.5 1.7
LV size, systole, mm** 31.2 5.9
LV size, diastole, mm†† 48.8 5.6
Values are mean  SD or n (%). *Body mass index available for 1,748
1,760 patients. ‡Left atrial volume available for 1,690 (96.0%) of 1,76
Left ventricular (LV) mass index available for ¶septal wall thickness wa
available in 1,637 (93.0%) of 1,760 patients. **LV size, systole, was av
in 1,707 (97.0%) of 1,760 patients.
E  passive transmitral left ventricular inflow velocity; e=  tissue Dion, coronary disease, ejection fraction, left atrial volume,eceleration time, and LV mass index (HR: 1.61, 95% CI:
.17 to 2.20; p  0.003) (Table 2).
ssociation of diastolic dysfunction and death. Diastolic
ysfunction (defined as an E/e= ratio 15) was predictive of
eath in Kaplan-Meier analysis (Fig. 2). The cumulative
robability of death for diabetic patients with diastolic
ysfunction was 6.9% at 1 year and 30.8% at 5 years
ompared with 3.1% at 1 year and 12.1% at 5 years for
iabetic patients without diastolic dysfunction (p  0.001).
Diastolic Dysfunction
Present
(n  411)
Absent
(n  1,349) p Value
67 13 58 14 0.001
160 (39) 703 (52) 0.001
31 9 33 15 0.01
374 (91) 1,133 (84) 0.007
178 (43) 454 (34) 0.007
61 11 62 8 0.005
21 6 11 3 0.001
73 25 60 23 0.001
216 69 217 46 0.49
107 29 94 23 0.001
11.4 2.1 10.8 1.8 0.001
10.9 1.8 10.4 1.6 0.001
31.4 7.0 31.1 5.5 0.40
50.0 5.9 48.7 5.5 0.47
) of 1,760 patients. †Ejection fraction available for 1,692 (96.1%) of
nts. §Deceleration time available for 1,631 (92.7%) of 1,760 patients.
ble in 1,646 (93.5%) of 1,760 patients. #Posterior wall thickness was
in 1,546 (84.8%) of 1,760 patients. ††LV size, diastole, was available
imaging velocity of the medial mitral annulus during passive filling.
Figure 1 Kaplan-Meier Analysis of Diastolic
Dysfunction and Subsequent HF in Diabetic Patients
Diastolic dysfunction defined as passive transmitral left ventricular inflow veloc-
ity to tissue Doppler imaging velocity of the medial mitral annulus during pas-
sive filling (E/e=) ratio 15 is predictive of heart failure (HF) in Kaplan-Meier
analysis. The cumulative probability of the development of HF for diabetic
patients with diastolic dysfunction is 13.1% at 1 year and 36.9% at 5 years
compared with 5.2% at 1 year and 16.8% at 5 years for diabetic patients with-
out diastolic dysfunction. p  0.001.(99.3%
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January 26, 2010:300–5 HF in Diabetic Diastolic Dysfunctionn multivariable Cox’s proportional hazard regression anal-
sis, we determined that diastolic dysfunction was associated
ith death after adjustment for age, sex, body mass index,
ypertension, coronary disease, ejection fraction, left atrial
olume, deceleration time, and LV mass index (HR: 2.01,
5% CI: 1.32 to 3.06; p  0.001).
ssociation of diastolic dysfunction and atrial fibrilla-
ion. To assess the association between diastolic dysfunc-
ion and the subsequent development of atrial fibrillation,
e analyzed the 1,450 patients without a previous diagnosis
f atrial fibrillation before the date of the echocardiogram.
mong this subgroup, the cumulative probability of subse-
uent atrial fibrillation for diabetic patients with diastolic
ysfunction was 6.8% at 1 year and 18.7% at 5 years
ompared with 3.1% at 1 year and 8.8% at 5 years for
iabetic patients without diastolic dysfunction (p  0.001).
n multivariable Cox’s proportional hazard regression anal-
sis, we determined that diastolic dysfunction was not
ignificantly associated with the subsequent development of
trial fibrillation after adjustment for age, sex, body mass
ndex, hypertension, coronary disease, ejection fraction, left
trial volume, deceleration time, and LV mass index (HR:
.16, 95% CI: 0.75 to 1.76; p  0.50).
ubgroup analyses. In subgroup analysis of 1,356 diabetic
atients with a diagnosis of hypertension before the date of
chocardiography, diastolic dysfunction was independently
redictive of subsequent HF (HR: 1.67, 95% CI: 1.20 to
.33; p  0.003) and death (HR: 2.14, 95% CI: 1.36 to
.36; p  0.001) after adjustment for age, sex, body mass
ndex, coronary disease, ejection fraction, left atrial volume
eceleration time, and LV mass index. However, after
djustment for these variables, diastolic dysfunction was not
ndependently associated with the subsequent development
f atrial fibrillation (HR: 1.01, 95% CI: 0.62 to 1.63; p 
.95).
We used the criteria outlined by Lang et al. (23) for the
easurement of relative wall thickness and the classification
f left ventricle geometry. In 1,616 patients, the left ven-
ricular geometry could be defined. A total of 554 (34%) had
ultivariable Associationsith Subsequent He rt FailureTable 2 Mul ivariable AssociationsWith Subsequent Heart Failure
Characteristic
Multivariable Analysis,
HR (95% CI) p Value
Age 1.03 (1.02–1.05) 0.001
Male sex 0.99 (0.72–1.36) 0.97
Body mass index 1.00 (0.99–1.01) 0.34
Hypertension 4.27 (1.92–12.15) 0.001
Coronary disease 2.20 (1.62–3.01) 0.001
Ejection fraction 0.96 (0.95–0.98) 0.001
E/e= 15 (diastolic dysfunction) 1.61 (1.17–2.20) 0.003
Left atrial volume 1.00 (1.00–1.01) 0.08
Deceleration time 1.00 (1.00–1.00) 0.98
LV mass index 1.01 (1.00–1.01) 0.01
I  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.ormal geometry, 524 (32%) had concentric remodeling,43 (21%) had concentric hypertrophy, and 195 (12%) had
ccentric hypertrophy.
In multivariable analysis with adjustment for age, sex,
ody mass index, hypertension, coronary disease, ejection
raction, left atrial volume, deceleration time, LV mass
ndex, and relative wall thickness (as a continuous variable),
iastolic dysfunction was independently associated with the
ubsequent development of HF (HR: 1.63, 95% CI: 1.20 to
.21; p  002) and death (HR: 2.13, 95% CI: 1.43 to 3.15;
 002).
In multivariable analysis with adjustment for age, sex,
ody mass index, hypertension, coronary disease, ejection
raction, left atrial volume, deceleration time, and geometric
attern of the left ventricle (as a categorical variable),
iastolic dysfunction was independently associated with the
ubsequent development of HF (HR: 1.62, 95% CI: 1.19 to
.19; p  002) and death (HR: 2.18, 95% CI: 1.48 to 3.20;
 0.001).
iscussion
he present study is the first to use a community-based
ohort of diabetic patients to determine whether HF is more
ikely to develop in those with pre-clinical diastolic dysfunc-
ion compared with those without diastolic dysfunction.
ur current findings demonstrate that pre-clinical diastolic
ysfunction is common in patients with DM and confirms
hat pre-clinical diastolic dysfunction in those with DM is
ssociated with an increased risk of the subsequent devel-
pment of HF, mortality, and atrial fibrillation.
re-clinical diastolic dysfunction in DM. Pre-clinical
iastolic dysfunction has been broadly defined as diastolic
ysfunction in patients with normal systolic function and no
Figure 2 Kaplan-Meier Analysis of Diastolic
Dysfunction and Death in Diabetic Patients
Diastolic dysfunction defined as passive transmitral left ventricular inflow veloc-
ity to tissue Doppler imaging velocity of the medial mitral annulus during pas-
sive filling (E/e=) ratio 15 is predictive of death in Kaplan-Meier analysis. The
cumulative probability of death for diabetic patients with diastolic dysfunction
is 6.9% at 1 year and 30.8% at 5 years compared with 3.1% at 1 year and
12.1% at 5 years for diabetic patients without diastolic dysfunction. p  0.001.
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HF in Diabetic Diastolic Dysfunction January 26, 2010:300–5ymptoms of HF (15,24). In diabetic patients, the existence
f a pre-clinical diastolic dysfunction has been well defined
nd estimates of prevalence vary from 20% to 60% depend-
ng on the Doppler echocardiographic criteria that was used
o define diastolic dysfunction (1–9). Several lines of evi-
ence indicate that LV diastolic dysfunction may precede
V systolic dysfunction in diabetic patients (15,20). This
arly restrictive disease seen in diabetic patients is likely due to
icroangiopathy, interstitial fibrosis, extracellular collagen
eposition, calcium transport abnormalities, and neurohor-
onal alterations, alone or in combination (12–14). Regan et
l. (25) conducted a cardiac catheterization study that demon-
trated that normotensive diabetic patients with normal ejec-
ion fraction without coronary artery disease and without
linical evidence of HF have an increased LV end-diastolic
ressure and a decreased LV end-diastolic volume. Although
ystolic dysfunction, LV hypertrophy, coronary disease, and
ypertension have all been shown to increase the risk of the
evelopment of HF in DM patients, the prognostic impact of
re-clinical diastolic dysfunction in DM patients has not been
ell defined, but the association with the subsequent develop-
ent of HF has been suspected (16).
We determined that the prevalence of pre-clinical LV
iastolic dysfunction in our population was 23%. We also
emonstrated that pre-clinical diastolic dysfunction in DM
atients was associated with an increased risk of the subse-
uent development of HF and mortality after adjustment
or multiple demographic, echocardiographic variables, hy-
ertension, and coronary disease. Although novel, these
ndings were hypothesized based on the known associations
etween diastolic dysfunction, HF, DM, and mortality.
reviously, Redfield et al. (24) demonstrated that even mild
iastolic dysfunction conferred a risk of increased mortality
ompared with subjects with normal diastolic function in
he general population. Furthermore, DM is a well-
ecognized risk factor for the development of HF as
emonstrated by the report from the Framingham Heart
tudy that showed that HF occurred 2 times more often in
en with DM and 5 times more often in women with DM
ompared with age-matched control subjects. Likewise, we
reviously reported that the prevalence of DM in patients
ith HF is approximately 20%, and DM is associated with
ncreased mortality in patients with HF (26), whereas
ribouilloy et al. (27) reported a markedly increased mor-
ality rate in patients with HF and preserved ejection
raction among patients with DM compared with patients
ithout DM.
The cited studies focus on the E-to-A ratio to diagnose
iastolic dysfunction. The difference between the E-to-A
atio and the E/e= ratio is physiopathological: The E-to-A
atio is 1 when the relaxation is abnormal and LV filling
ressure is still normal, but becomes 1 when LV filling
ressure increases. Indeed, there are limitations of a cate-
orical variable such as the E-to-A ratio as shown in an
nalysis of the Strong Heart Study by Bella et al. (28) in
hich high values of the E-to-A ratio predict mortalityompared with low values, which do not. On the other
and, the E/e= ratio has a continuous behavior because its
ncrease is always an expression of increased LV filling
ressure. As we have shown with our cohort of diabetic
atients, an increase in the E/e= ratio is associated with
ncreasing risk of subsequent HF.
uture directions. Despite the current medical therapy for
F and DM, our current study demonstrates that the
revalence of pre-clinical diastolic dysfunction is high in
M patients and associated with worse outcomes. Further-
ore, we recently reported that there is a direct correlation
etween the duration of DM and diastolic dysfunction and
hat significant diastolic dysfunction occurs 4 years after the
nset of DM independent of coronary disease or hyperten-
ion (20). Therefore, future studies should be conducted to
est the hypothesis that screening and aggressive manage-
ent of diabetic patients with pre-clinical diastolic dysfunc-
ion may delay the progression to HF with improved
utcomes.
tudy limitations. The study was retrospective, we did not
ave data on medications or diabetes subtype, and the study
elied heavily on the International Classification of Disease–
th Revision coding variables to define HF. Although these
odes have been validated as a diagnostic and research tool
n Olmsted County, Minnesota, they do allow for potential
ias. Furthermore, the patients were not recruited from the
ommunity, but were clinically referred for echocardiogra-
hy by their primary physicians, which may decrease the
eneralizability of the results. Finally, although the diversity
f the Olmsted County population is increasing, as shown
y the 2000 census (29), characteristics of the Olmsted
ounty population are similar to those of U.S. whites (19).
hus, these findings should be examined in different racial
nd ethnic groups.
onclusions
his study confirms that pre-clinical diastolic dysfunction is
revalent in patients with DM. More importantly, we
emonstrated that an increase in the E/e= ratio in diabetic
atients was associated with subsequent HF and mortality
ndependent of hypertension, coronary disease, and other
chocardiographic parameters.
eprint requests and correspondence: Dr. Horng H. Chen, Divi-
ion of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW,
ochester, Minnesota 55905. E-mail: chen.horng@mayo.edu.
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